Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy
Open Access
- 23 August 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (3), 67
- https://doi.org/10.3390/ijns6030067
Abstract
Newborn screening for 21-hydroxylase deficiency (21OHD), the most common form of congenital adrenal hyperplasia, has been performed routinely in the United States and other countries for over 20 years. Screening provides the opportunity for early detection and treatment of patients with 21OHD, preventing salt-wasting crisis during the first weeks of life. However, current first-tier screening methodologies lack specificity, leading to a large number of false positive cases, and adequate sensitivity to detect all cases of classic 21OHD that would benefit from treatment. This review summarizes the pathology of 21OHD and also the key stages of fetal hypothalamic-pituitary-adrenal axis development and adrenal steroidogenesis that contribute to limitations in screening accuracy. Factors leading to both false positive and false negative results are highlighted, along with specimen collection best practices used by laboratories in the United States and worldwide. This comprehensive review provides context and insight into the limitations of newborn screening for 21OHD for laboratorians, primary care physicians, and endocrinologists.Keywords
This publication has 65 references indexed in Scilit:
- Comparison of One-Tier and Two-Tier Newborn Screening Metrics for Congenital Adrenal HyperplasiaPEDIATRICS, 2012
- False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)–ether extraction reveals two distinct reasons for elevated 17α-hydroxyprogesterone (17-OHP) valuesSteroids, 2009
- Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girlsThe Journal of Pediatrics, 2005
- Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia by Second-Tier Steroid Profiling Using Tandem Mass SpectrometryClinical Chemistry, 2004
- Genotyping Is a Valuable Diagnostic Complement to Neonatal Screening for Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase DeficiencyJournal of Clinical Endocrinology & Metabolism, 1999
- Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal HyperplasiaPEDIATRICS, 1998
- Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levelsThe Journal of Pediatrics, 1997
- Adrenocortical function in the very low birth weight infant: Improved testing sensitivity and association with neonatal outcomeThe Journal of Pediatrics, 1996
- Newborn Screening for Congenital Adrenal Hyperplasia with Special Reference to Screening in AlaskaaAnnals of the New York Academy of Sciences, 1985
- Plasma 17-hydroxyprogesterone concentrations in ill newborn infants.Archives of Disease in Childhood, 1983